The death of a British nurse has been linked for the first time to the use of Mongaro, which contains the active ingredient tirzepatide, which is used to treat obesity.
London says it wants to expand the base of beneficiaries of “Monjaro” to relieve pressure on the country’s public health system, according to what the British Broadcasting Corporation (BBC) reported the day before yesterday, Friday.
Nurse Susan McGowan (58 years old) died of multiple organ failure, septic shock, and pancreatitis, and “use of the prescribed drug terzipatide” was a contributing factor to her death, according to what was stated in her death certificate, the details of which were reported by British media.
This molecule was developed by the giant American company Eli Lilly, which markets the Monjaro drug, which is similar to the famous Ozembic treatment.
McGowan had purchased the treatment without a prescription from an online pharmacy, but after her second injection, she began suffering from severe stomach pain and nausea, according to the BBC. She went to Monklands Hospital, where she was working in central Scotland, but her colleagues were unable to save her. .
In response to a question from the BBC, the Eli Lilly laboratory confirmedHe is fully committed to “continuous monitoring, evaluation and communication” regarding the safety of his medication.
In mid-October, the British government announced a partnership with this giant American pharmaceutical company, which planned to invest 279 million pounds ($360 million) in the United Kingdom.
Prime Minister Keir Starmer said at the time that Monjaro would be “very useful for people who want to lose weight, who need to, and with great importance for the economy so that people can get back to work.”
A clinical trial is being conducted in Manchester and will last 5 years to evaluate the effect of this treatment “in real life” with the participation of 3,000 people who suffer from obesity and are unemployed, working in temporary jobs, or on sick leave.
According to Health Minister Wes Streeting, obesity costs the NHS (the British public health system) 11 billion pounds annually.
The British Medicines Regulatory Agency told the BBC that the use of this new drug is being “closely monitored” to identify potential risks.
According to figures issued in January 2023, 26% of adults in England suffer from obesity, and 38% are overweight, which is one of the highest percentages in Europe.